PPMD — Protide Pharmaceuticals Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.68% | ||
| Return on Equity | -30.44% | ||
| Operating Margin | -17.06% | ||
Financial Summary
| Year End 31st Aug | Unit | 1999 | 2000 | 2001 | 2002 | 2003 | 2004E | 2005E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.2 | 0.2 | 0.2 | 0.41 | 0.5 | n/a | n/a | 13.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Protide Pharmaceuticals, Inc. is engaged in the discovery, development and advancement of technologies and processes in clinical cell therapy, regenerative medicine, transplantation and cell engineering. The Company offers a range of products, including serum replacements, cryopreservatives, cell processing and cell islet transplantation (CIT) islet cell solutions. The Company’s serum replacements product enables insight into cellular processes, as well as commercial production of recombinant therapeutic proteins, vaccines and other biological proteins. Its serum replacements product includes TCH, VaxMax, HemaPro, TM-235 and TCM. Its cryopreservatives products include Stemsol USP (DMSO), pZerve, Cellvation, MiCord 55% DMSO USP 5% Dextran USP and 2-8CELLsius + DMSO. Its cell processing products include 2-8CELLsius, Dextran 40 in 0.9% NaCl, Dulbecco’s Phosphate Buffered Saline (10X) PBS, Dulbecco’s Phosphate Buffered Saline (1X) PBS and Hank’s Balanced Salt Solution (1X) HBSS.
Directors
- Last Annual
- August 31st, 2003
- Last Interim
- February 28th, 2004
- Incorporated
- February 25th, 1988
- Public Since
- July 19th, 1996
- No. of Shareholders
- 600
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,029,134
- Address
- 345 Memorial Drive, Suite A, CRYSTAL LAKE, 60014
- Web
- https://www.protidepharma.com/
- Phone
- +1 8477263100
- Auditors
- Wipfli Ullrich Bertelson
Similar to PPMD
Acer Therapeutics
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 18:17 UTC, shares in Protide Pharmaceuticals are trading at $0.22. This share price information is delayed by 15 minutes.
Shares in Protide Pharmaceuticals last closed at $0.22 and the price had moved by +37.5% over the past 365 days. In terms of relative price strength the Protide Pharmaceuticals share price has outperformed the S&P500 Index by +24.42% over the past year.
There is no consensus recommendation for this security.
Protide Pharmaceuticals does not currently pay a dividend.
Protide Pharmaceuticals does not currently pay a dividend.
Protide Pharmaceuticals does not currently pay a dividend.
To buy shares in Protide Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.22, shares in Protide Pharmaceuticals had a market capitalisation of .
Here are the trading details for Protide Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PPMD
Based on an overall assessment of its quality, value and momentum Protide Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Protide Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +76.37%.
As of the last closing price of $0.22, shares in Protide Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Protide Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Protide Pharmaceuticals' management team is headed by:
- Milo Polovina - CEO
- John Stoner - DRC